CCLD Quote, Financials, Valuation and Earnings

Astrana Health, Inc. has a net margin of 9.85% compared to CareCloud, Inc.'s net margin of 0.11%. CareCloud, Inc.'s return on equity of 21.2% beat Astrana Health, Inc.'s return on equity of 1.85%.

CareCloud, Inc. has a consensus price target of $6.31, signalling upside risk potential of 106.97%. On the other hand Astrana Health, Inc. has an analysts' consensus of $36.8889 which suggests that it could grow by 29.75%. Given that CareCloud, Inc. has higher upside potential than Astrana Health, Inc., analysts believe CareCloud, Inc. is more attractive than Astrana Health, Inc..

CareCloud, Inc. has a beta of 1.993, which suggesting that the stock is 99.347% more volatile than S&P 500. In comparison Astrana Health, Inc. has a beta of 0.866, suggesting its less volatile than the S&P 500 by 13.424%.

CareCloud, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Astrana Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CareCloud, Inc. pays -- of its earnings as a dividend. Astrana Health, Inc. pays out -- of its earnings as a dividend.

CareCloud, Inc. quarterly revenues are $31.1M, which are smaller than Astrana Health, Inc. quarterly revenues of $956M. CareCloud, Inc.'s net income of $3.1M is higher than Astrana Health, Inc.'s net income of $1.1M. Notably, CareCloud, Inc.'s price-to-earnings ratio is 74.94x while Astrana Health, Inc.'s PE ratio is 149.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CareCloud, Inc. is 0.83x versus 0.48x for Astrana Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Cryo-Cell International, Inc. has a net margin of 9.85% compared to CareCloud, Inc.'s net margin of 9.58%. CareCloud, Inc.'s return on equity of 21.2% beat Cryo-Cell International, Inc.'s return on equity of --.

CareCloud, Inc. has a consensus price target of $6.31, signalling upside risk potential of 106.97%. On the other hand Cryo-Cell International, Inc. has an analysts' consensus of $8.50 which suggests that it could grow by 139.44%. Given that Cryo-Cell International, Inc. has higher upside potential than CareCloud, Inc., analysts believe Cryo-Cell International, Inc. is more attractive than CareCloud, Inc..

CareCloud, Inc. has a beta of 1.993, which suggesting that the stock is 99.347% more volatile than S&P 500. In comparison Cryo-Cell International, Inc. has a beta of 0.689, suggesting its less volatile than the S&P 500 by 31.12%.

CareCloud, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cryo-Cell International, Inc. offers a yield of 18.31% to investors and pays a quarterly dividend of $0.15 per share. CareCloud, Inc. pays -- of its earnings as a dividend. Cryo-Cell International, Inc. pays out 510.2% of its earnings as a dividend.

CareCloud, Inc. quarterly revenues are $31.1M, which are larger than Cryo-Cell International, Inc. quarterly revenues of $7.8M. CareCloud, Inc.'s net income of $3.1M is higher than Cryo-Cell International, Inc.'s net income of $749.4K. Notably, CareCloud, Inc.'s price-to-earnings ratio is 74.94x while Cryo-Cell International, Inc.'s PE ratio is 498.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CareCloud, Inc. is 0.83x versus 0.91x for Cryo-Cell International, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Omnicell, Inc. has a net margin of 9.85% compared to CareCloud, Inc.'s net margin of 1.76%. CareCloud, Inc.'s return on equity of 21.2% beat Omnicell, Inc.'s return on equity of 1.6%.

CareCloud, Inc. has a consensus price target of $6.31, signalling upside risk potential of 106.97%. On the other hand Omnicell, Inc. has an analysts' consensus of $54.00 which suggests that it could grow by 6.43%. Given that CareCloud, Inc. has higher upside potential than Omnicell, Inc., analysts believe CareCloud, Inc. is more attractive than Omnicell, Inc..

CareCloud, Inc. has a beta of 1.993, which suggesting that the stock is 99.347% more volatile than S&P 500. In comparison Omnicell, Inc. has a beta of 0.773, suggesting its less volatile than the S&P 500 by 22.655%.

CareCloud, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Omnicell, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CareCloud, Inc. pays -- of its earnings as a dividend. Omnicell, Inc. pays out -- of its earnings as a dividend.

CareCloud, Inc. quarterly revenues are $31.1M, which are smaller than Omnicell, Inc. quarterly revenues of $310.6M. CareCloud, Inc.'s net income of $3.1M is lower than Omnicell, Inc.'s net income of $5.5M. Notably, CareCloud, Inc.'s price-to-earnings ratio is 74.94x while Omnicell, Inc.'s PE ratio is 119.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CareCloud, Inc. is 0.83x versus 2.01x for Omnicell, Inc.. Usually stocks with elevated PS ratios are considered overvalued.